It can be administered in-office or by self-injection after training. Developed in partnership with Germany’s Boehringer Ingelheim, Skyrizi was approved in Japan and Canada in the past few weeks.

The company’s follow-up drug Skyrizi is a key plank in AbbVie’s strategy to negotiate the $20 billion patent cliff from Humira, which has already seen sales decline outside of the US where it ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.